# VHAG in Treating R/R T-ALL/LBL

> **NCT06742463** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Acute T Lymphpblastic Leukemia/Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** homoharringtonine
- **DRUG:** Cytarabine (Ara-C)
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT06742463
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742463, "VHAG in Treating R/R T-ALL/LBL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06742463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*